{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:13:56Z","timestamp":1762431236310,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["15AeK0109050s0302"],"award-info":[{"award-number":["15AeK0109050s0302"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ymgmr.2016.11.001","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T19:16:05Z","timestamp":1479496565000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state"],"prefix":"10.1016","volume":"9","author":[{"given":"Takashi","family":"Matsuoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6975-7712","authenticated-orcid":false,"given":"Makiko","family":"Tajika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madoka","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Fujimaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Soga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6874-8491","authenticated-orcid":false,"given":"Hideshi","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichizo","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Sugie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motomichi","family":"Kosuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torayuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2016.11.001_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid \u03b1-glucosidase (acid maltase) deficiency","volume":"8","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0010","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ajmg.a.35662","article-title":"How to describe the clinical spectrum in Pompe disease?","volume":"161A","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jpeds.2004.01.053","article-title":"Pompe disease in infants and children","volume":"144","author":"Kishnani","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0030","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"15","author":"van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0040","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0045","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1542\/peds.2007-0388","article-title":"Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations","volume":"120","author":"Kemper","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0050","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","volume":"54","author":"Chien","year":"2013","journal-title":"Pediatr. Neonatol."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajmg.a.36197","article-title":"A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment","volume":"164A","author":"Yang","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0065","first-page":"133","article-title":"CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy","volume":"9","author":"Hamoud","year":"2013","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgmr.2016.11.001_bb0070","first-page":"30","article-title":"Immune tolerance strategies in siblings with infantile Pompe disease-advantages for a preemptive approach to high-sustained antibody titers","volume":"1","author":"Stenger","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"360","key":"10.1016\/j.ymgmr.2016.11.001_bb0075","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1056\/NEJMc0806809","article-title":"Elimination of antibodies to recombinant enzyme in Pompe's disease","volume":"8","author":"Mendelsohn","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0085","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0090","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab. Investig."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0095","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ymgme.2011.09.002","article-title":"Newborn screening for Pompe disease in Japan","volume":"104","author":"Oda","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0100","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth","volume":"166","author":"Chien","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2016.11.001_bb0105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","article-title":"Very early treatment for infantile-onset Pompe disease contributes to better outcomes","volume":"169","author":"Yang","year":"2016","journal-title":"J. Pediatr."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426916300878?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426916300878?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:49:30Z","timestamp":1762001370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426916300878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":21,"alternative-id":["S2214426916300878"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2016.11.001","relation":{},"ISSN":["2214-4269"],"issn-type":[{"type":"print","value":"2214-4269"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2016.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}